Juno Therapeutics Inc (NASDAQ:JUNO) shares rose 3.6% during trading on Wednesday . The company traded as high as $28.52 and last traded at $28.45, with a volume of 1,019,223 shares changing hands. The stock had previously closed at $27.47.

JUNO has been the topic of a number of recent analyst reports. Morgan Stanley upped their target price on shares of Juno Therapeutics from $48.00 to $50.00 in a research report on Friday, April 8th. FBR & Co reaffirmed a “buy” rating and issued a $73.00 target price on shares of Juno Therapeutics in a research report on Saturday, April 9th. Maxim Group reaffirmed a “buy” rating and issued a $80.00 target price (up previously from $78.00) on shares of Juno Therapeutics in a research report on Monday, April 11th. Zacks Investment Research cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 15th. Finally, SunTrust Banks Inc. reaffirmed a “buy” rating and issued a $50.00 target price on shares of Juno Therapeutics in a research report on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $54.84.

The stock’s market cap is $2.92 billion. The firm has a 50 day moving average price of $38.45 and a 200-day moving average price of $37.61.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.26. The company earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. During the same period in the previous year, the company posted ($0.30) EPS. Equities research analysts predict that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 90,750 shares of the firm’s stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $46.42, for a total value of $4,212,615.00. Following the sale, the chief executive officer now directly owns 2,704,609 shares of the company’s stock, valued at approximately $125,547,949.78. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Steve Harr sold 30,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $43.32, for a total value of $1,299,600.00. Following the completion of the sale, the chief financial officer now directly owns 716,052 shares in the company, valued at $31,019,372.64. The disclosure for this sale can be found here.

A number of hedge funds have modified their holdings of the company. Baillie Gifford & Co. acquired a new stake in shares of Juno Therapeutics during the fourth quarter worth about $12,312,000. California Public Employees Retirement System raised its stake in shares of Juno Therapeutics by 878.7% in the fourth quarter. California Public Employees Retirement System now owns 105,700 shares of the biopharmaceutical company’s stock worth $4,648,000 after buying an additional 94,900 shares during the last quarter. Swiss National Bank acquired a new stake in shares of Juno Therapeutics during the fourth quarter worth about $2,603,000. BBR Partners LLC acquired a new stake in shares of Juno Therapeutics during the fourth quarter worth about $1,539,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares during the last quarter.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.